Karlsruhe, Germany

Karsten Schmidt


 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Karsten Schmidt: Innovator in Sialyltransferase Production

Introduction

Karsten Schmidt is a notable inventor based in Karlsruhe, Germany. He has made significant contributions to the field of biochemistry, particularly in the production and purification of sialyltransferase polypeptides. His work has implications for the development of therapeutic proteins, showcasing the intersection of innovation and healthcare.

Latest Patents

Karsten Schmidt holds a patent for a method of producing and purifying an active soluble sialyltransferase. This invention specifically relates to the N-Acetylgalactosamine (Gal NAc)-α-2,6-sialyltransferase I (ST6GalNAcI) polypeptide. The patented method involves producing the sialyltransferase polypeptide in Chinese Hamster Ovary (CHO) cells and purifying it through a series of chromatography steps. This process results in a high yield of a highly pure and active sialyltransferase polypeptide, which can be utilized for glycosylating therapeutic proteins such as G-CSF.

Career Highlights

Throughout his career, Karsten Schmidt has worked with several prominent companies in the pharmaceutical and biotechnology sectors. Notable among these are Biogenerix GmbH and Ratiopharm GmbH. His experience in these organizations has contributed to his expertise in the field and has facilitated his innovative work.

Collaborations

Karsten Schmidt has collaborated with several professionals in his field, including Axel Angermann and Christian Scheckermann. These collaborations have likely enriched his research and development efforts, leading to advancements in his patented methods.

Conclusion

Karsten Schmidt's contributions to the production and purification of sialyltransferase polypeptides highlight his role as an innovator in biochemistry. His patent and career achievements reflect a commitment to advancing therapeutic protein development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…